NOVO expected to reach ATH during 2026Based on EW count and general knowledge about the company, it is expected that Novo will get back to the top (approx x2 from here) during 2026. Lets see
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.5 USD
14.65 B USD
42.12 B USD
3.37 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
FIGI
BBG00JVRG3N5
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
NVO Soaring Towards TargetsOur NVO call debit spreads and LEAPS options soaring towards targets at the 233 EMA here.
Beautiful thing when fundamentals, valuations and technicals align.
Impulse move from the bottom gave us a hat trick - triple green tags (white circles) for bullish A+ momentum signals into a consolidation p
NOVO is looking at a strong bullish bottoming outNYSE:NVO is looking at a strong bullish reversal and is likely to head higher after stochastic shows overbought AND long term stochastic shows clear confirmation of oversold crossover.
Price action shows a clear break out of the downtrend line and with the rounding bottom, the stock is likely to
NVO bounce off of Ozempic launch AVWAPOzempic launched Feb 5 2018. Anchoring our VWAP to that date we get our confirmation of a strong anchor from the COVID bounce, indicating institutional buying at that level. Over 7 years later, we get another opportunity.
Novo Nordisk: Massive buying opportunityNovo has been struggling big time, december and march hit especially hard.
American institutions have held large positions in Novo, and this was felt when they had to sell off due to risk management with the looming tariffs.
However, the sheer devaluation & importance of their export, is going to
nvo bullish long Long Setup Idea – Not Financial Advice - AH
This is a long trade setup based on my personal analysis.
The entry, stop-loss, and target levels are outlined for educational and illustrative purposes only.
📈 Entry:
🛑 Stop Loss:
🎯 Target(s):
Disclaimer:
I am not a financial advisor. This idea i
NVO Exhibits High Monthly Volume Amid Downtrend – SHortNVO Exhibits High Monthly Volume Amid Downtrend – Potential Accumulation Phase
📉 Post:
Novo Nordisk (NVO) has experienced a significant decline from its 52-week high of $148.15 to a recent low of $57.00. However, the monthly chart reveals an unusually high trading volume, which may indicate accumul
The most profitable drug known to man. Liquid goldThe title speaks for itself self.
Weekly RSI retesting a 10yr low.
Ozempic (GLP1) is and will continue to be the most profitable drug known to man.
Novo 1h longShould get up and at least break the neckline from the bigger SHS/IHS.
Stop below zone or lower trendline.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where 0TDD is featured.
